ERBB2 and breast carcinoma: The cross-assay comparison was then extended to include two HER2-enriched TMAs (TMA226 and 227) from a cohort of samples from patients who were diagnosed with their primary breast cancer between March 1995 and November 2005 and subsequently treated at the Dana-Farber/Brigham and Women’s Cancer Center (Table 3).